Financial Data and Key Metrics Changes - Q4 2025 revenue was $64.6 million, a 45.2% increase compared to Q4 2024, with total revenue for 2025 reaching $211.1 million, up 27.2% from 2024 [3][4] - Q4 net loss from operations was $3.9 million, down 79% from Q4 2024, while adjusted EBITDA was positive at $5.5 million, compared to a loss of $13.1 million in Q4 2024 [4][24] - The ending cash balance for 2025 was $75.6 million, indicating no need for additional capital [4] Business Line Data and Key Metrics Changes - U.S. Motiva revenue in 2025 was $45.6 million, contributing significantly to overall growth [3] - Gross margin for Q4 was 70.5%, a 200 basis point increase from the previous year, with overall gross profit margin increasing 330 basis points in 2025 [22][23] Market Data and Key Metrics Changes - Sales in Europe, the Middle East, and Africa accounted for 41% of global total sales in Q4, with strong growth in direct markets [22] - Latin America represented 18% of sales, with stable results in Brazil and strong growth in Argentina [22][23] - Asia Pacific accounted for 14.1% of sales, with improved performance in China [22][19] Company Strategy and Development Direction - The company aims to transform the breast aesthetics industry through innovation, with a focus on minimally invasive procedures like Preservé [6][12] - Plans to expand the U.S. sales force by adding up to 15 more representatives to drive market penetration [11][26] - The introduction of Motiva implants for breast reconstruction is expected to double the total addressable market in the U.S. [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity in 2026 and expects significant growth in 2027 [4][30] - The U.S. market remains healthy, with strong demand for breast augmentation procedures and a positive outlook for the minimally invasive portfolio [52][60] - The company is focused on maintaining operational momentum while preparing for future growth phases [20][21] Other Important Information - The company is actively working on FDA approvals for new products, including smaller sizes and reconstruction options, which are expected to enhance market share [18][69] - Establishment Labs is also considering refinancing options for its credit facility as it approaches the end of its term [26] Q&A Session Summary Question: Thoughts on the minimally invasive portfolio and market growth - Management noted strong early experiences with Preservé and Mia, indicating a positive trajectory for market growth and patient interest [33][35] Question: U.S. revenue and sales representative expansion - The company is focused on hiring experienced sales representatives to enhance market penetration and drive growth [36][38] Question: Plans for reconstruction market entry - Management highlighted the significant opportunity in the reconstruction market, with plans to expand the sales force and leverage existing relationships [40][41] Question: International growth and underlying demand - Management confirmed that international markets are showing healthy demand, with no significant one-off factors affecting growth [43][44] Question: Global market conditions and augmentation procedures - The overall market for breast augmentation procedures is healthy, with increasing interest and demand across various regions [51][54] Question: Contribution of pipeline products to revenue guidance - Reconstruction is expected to be more of a 2027 story, while Preservé is anticipated to drive significant revenue growth in 2026 [68][70]

Financial Data and Key Metrics Changes - Q4 2025 revenue was $64.6 million, a 45.2% increase compared to Q4 2024, with total revenue for 2025 reaching $211.1 million, up 27.2% from 2024 [3][4] - Q4 net loss from operations was $3.9 million, down 79% from Q4 2024, while adjusted EBITDA for Q4 was $5.5 million, improving from a loss of $13.1 million in Q4 2024 [4][24] - Gross margin for Q4 was 70.5%, a 200 basis point increase from 68.5% in the previous year, with an overall gross profit margin increase of 330 basis points for 2025 compared to 2024 [22][23] Business Line Data and Key Metrics Changes - US Motiva revenue in 2025 was $45.6 million, significantly exceeding expectations, contributing to approximately 20% market share by the end of 2025 [5][6] - The minimally invasive breast augmentation platform, Preserve, is expected to generate over $30 million in demand in 2026, with strong early adoption and interest from both patients and surgeons [15][20] - The company has onboarded over 1,500 accounts since the launch of Motiva, with continued growth in the number of practices [9][11] Market Data and Key Metrics Changes - Sales in Europe, the Middle East, and Africa accounted for 41% of global sales in Q4, with over 20% growth in direct markets [22][23] - Latin America contributed 18% of sales, with stable results in Brazil and strong growth in Argentina [22][23] - Asia Pacific represented 14.1% of sales, with improved performance in China noted as a key focus area [22][19] Company Strategy and Development Direction - The company aims to expand its US sales force by adding up to 15 more representatives, focusing on experienced industry veterans to drive market penetration [11][38] - Establishment Labs is positioning itself as a leader in breast aesthetics through innovation and a strong R&D pipeline, with plans to introduce new products and expand into reconstruction markets [6][17] - The company is actively working on FDA approvals for new products, including Motiva implants for breast reconstruction, which could double the total addressable market in the US [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity in 2026, with expectations for significant earnings growth in 2027 and beyond [4][30] - The overall market for breast augmentation procedures is healthy, with increasing interest and demand noted from both patients and surgeons [52][54] - The company is focused on maintaining operational momentum while ensuring strong leadership and oversight for future growth initiatives [20][21] Other Important Information - The company has a strong cash balance of $75.6 million, indicating no immediate need for additional capital [4][26] - Establishment Labs is working towards inclusion in various indices, including the Russell, which could enhance visibility and shareholder value [28] Q&A Session Summary Question: Thoughts on the minimally invasive portfolio and market growth - Management highlighted strong early experiences with Preserve and Mia, indicating optimism for market growth and potential to double breast augmentation procedure volumes [33][35] Question: Plans for expanding the US sales force - The company is focused on hiring experienced reps from the industry, which is expected to drive productivity and market share growth [36][38] Question: Insights on the reconstruction market and FDA approval - Management indicated that reconstruction is likely a 2027 story, with strong interest from hospitals already noted [40][42] Question: International growth and underlying demand - Management confirmed that international markets are performing well, with no significant one-offs affecting growth, and demand remains stable [43][45] Question: Global market outlook and macroeconomic conditions - Management noted that the underlying markets are healthy, with strong growth in both US and international markets, particularly in direct markets [51][54] Question: Contribution of new products to revenue guidance - Management indicated that while reconstruction may not significantly impact 2026, Preserve is expected to drive substantial revenue growth [68][70] Question: Spending cadence and operational expenses - Management expects spending to be non-linear, with a potential increase in the back half of the year as they support US expansion [72][74]

Financial Data and Key Metrics Changes - Q4 2025 revenue reached $64.6 million, a 45.2% increase compared to Q4 2024, with total revenue for 2025 at $211.1 million, up 27.2% from 2024 [4][22] - Q4 net loss from operations was $3.9 million, down 79% from Q4 2024, while adjusted EBITDA for Q4 was $5.5 million, a significant improvement from a loss of $13.1 million in Q4 2024 [5][24] - The company ended 2025 with a cash balance of $75.6 million, indicating no need for additional capital [5] Business Line Data and Key Metrics Changes - U.S. Motiva revenue for 2025 was $45.6 million, significantly exceeding expectations, contributing to approximately 20% market share by the end of 2025 [6][22] - Gross margin for Q4 was 70%, marking the second consecutive quarter of achieving this level, with an overall increase of 330 basis points in gross profit margin for 2025 compared to 2024 [4][23] Market Data and Key Metrics Changes - Sales in Europe, the Middle East, and Africa accounted for 41% of global sales in Q4, with strong growth in direct markets exceeding 20% [22] - Latin America represented 18% of sales, with Brazil stabilizing and Argentina showing strong growth [22] - Asia Pacific contributed 14.1% to sales, with improved performance in China noted [22][19] Company Strategy and Development Direction - The company aims to transform the breast aesthetics industry through innovation, with a strong R&D pipeline since 2010 [6][8] - Plans to expand the U.S. sales force by adding up to 15 more representatives to drive market share [11] - The introduction of minimally invasive breast augmentation through Preservé is expected to significantly expand the market and procedure volumes [12][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity in 2026 and anticipates significant growth in 2027 [5][30] - The company highlighted a healthy demand across all markets, with expectations for continued strong performance in the U.S. and international markets [27][52] - Management noted that the adoption of Motiva is still early, with significant room for growth in practice adoption and account penetration [27][60] Other Important Information - The company is actively working on FDA approvals for new products, including Motiva implants for breast reconstruction, which could double the total addressable market in the U.S. [17][70] - The transition in management roles is aimed at sustaining operational momentum and ensuring oversight of strategic initiatives [20][21] Q&A Session Summary Question: Insights on the minimally invasive portfolio and market growth - Management noted positive early experiences with the minimally invasive platform, indicating it could drive significant market growth and bring new patients to breast augmentation [33][35] Question: U.S. revenue growth and sales representative strategy - The company is focused on hiring experienced sales representatives from the industry to enhance productivity and drive growth in the U.S. market [36][39] Question: Plans for reconstruction market entry and sales strategy - Management discussed the importance of expanding the sales force and establishing hospital contracts to capitalize on the reconstruction market opportunity [41][42] Question: International growth and underlying demand - Management confirmed that international growth is stable, with no significant one-off factors affecting results, driven by strong demand and execution [44][45] Question: Expectations for the Chinese market and growth hurdles - The company is optimistic about the Chinese market, noting improvements in distributor performance and a focus on building commercial capabilities [83][84]